

Minimize device frustrations with the only ONE YEAR CGM.



# Talk to your healthcare provider about Eversense 365

### **Problem**

## **Eversense 365 solution**

Traditional, 10-14 day CGMs can fail early and unexpectedly



#### The longest lasting CGM

The only CGM that last for a year while traditional CGMs last 10-14 days, and tend to fail early.1-3

You waste a traditional, short-term CGM when you knock it off



#### Knock our CGM off, put it right back on

Our removable\* smart transmitter can be taken off and put back on.

Disruptive false alerts



## Fewer false alerts, including while you're asleep4

Eversense 365 has exceptional accuracy for one year, with almost no false compression low alerts.

Harsh adhesives and irritating self-insertions



#### Designed to reduce skin irritation

Our gentle, silicone-based adhesives are changed daily and cause almost no skin reactions.

EversenseCGM.com



# ONE YEAR. ONE COM.

Eversense 365 is the only ONE YEAR CGM, and it's designed to help minimize device frustrations so your patients can manage diabetes-and their daily life.

# Why Eversense 365?



The longest lasting and most dependable CGM1-3

The most accurate CGM in the hypoglycemic range1-3 and essentially no compression lows4






No more frequent CGM changes and wasted sensors1-3

## How Eversense 365 works

A healthcare provider places the one year sensor under the skin of the upper arm



The gentle silicone-based adhesive is replaced daily



The sensor sends real-time glucose data to the smart transmitter



The removable\* smart transmitter sends glucose data to the app



## Easy to get your patients started

- Prescribe Eversense 365
- The Eversense Inserter Network will manage the insertion process
- You continue your patient care



Learn More and get started today!

© 2024 Senseonics, Inc. All rights reserved.
© 2024 Ascensia Diabetes Care Holdings AG



Distributed by Ascensia Diabetes Care 5 Wood Hollow Road Parsippany, NJ 07054 844-SENSE4U (736-7348)

Manufactured by Senseonics, Inc.

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense 365 CGM System is a prescription device; patients should talk to their healthcare provider to learn more.

#### For safety information, see bit.ly/eversensesafety

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective holders and are used solely for informative purposes. No relationship or endorsement should be inferred or

PP-CGM-GBL-0024

- 1. Abbott. (2024) Freestyle Libre 3 User Guide ART49385-001 Rev. A 04/24
  2. Dexcom (2024) G7 User Guide AW00078-10 Rev 003 MT-00078-10
  3. Senseonics. (2024) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001 Rev A
- 4. Christiansen MP et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor. PRECISE II. DIABETES TECHNOLOGY & THERAPEUTICS 2018; 20(3):197-206 S. Senseonics, (2023) Eversense E O continuous Glucose Monitoring System User Guide. Bll-6002-01-001\_Rev D 6. Garg, Satish K., et al. (2022) "Evaluation of accuracy and safety of the next-generation up to 180-day long-term in John James (1997) and the state of the st
- 8. Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. Diabetes Technology and Therapeutics, 22(1), 48–52. https://doi.org/10.1089/dia.2019.0159
- 9. Diedisheim M., et. al. (2023). Prevalence and Description of the Skin Reactions Associated with Adhesives on
- Diabetes Technology
  Devices in an Adult Population: Results of the CUTADIAB Study. DIABETES TECHNOLOGY & THERAPEUTICS; 25(4):
  279-286 DOI:10.1089/dia.2022.0513